论文部分内容阅读
肺癌在世界各国的发病率及死亡率急剧上升。我国肺癌的死亡率占全部恶性肿瘤的7.56%,列于第5位,而且工业较发达的城市偏高。据估计80%~+患者诊断时已属Ⅲ期。化疗对50%以上刚确诊的肺癌及90%以上的某一阶段肺癌,皆有其适应症。1980年第二届世界肺癌学术会议上,比较明确地把肺癌分成两大类,即非小细胞肺癌(Non-small cell br-onchogenic carcinoma,NSBC)及小细胞肺癌。前者占72.1%,依次为鳞癌(30.4%),腺癌(23.1%),大细胞癌(18.6%)。因此,NSBC的药物治疗受到广泛的重视。本文简要介绍单
The incidence of lung cancer and death rates in all countries in the world have risen sharply. The mortality rate of lung cancer in our country accounts for 7.56% of all malignant tumors, and it is ranked in the fifth place, and the industrially more developed cities are higher. It is estimated that 80%~+ patients have been diagnosed with stage III. Chemotherapy has indications for more than 50% of newly diagnosed lung cancers and more than 90% of lung cancers at a certain stage. At the Second World Lung Cancer Academic Conference in 1980, lung cancer was more clearly divided into two categories: Non-small cell br-oncogenic carcinoma (NSBC) and small cell lung cancer. The former accounted for 72.1%, followed by squamous cell carcinoma (30.4%), adenocarcinoma (23.1%), and large cell carcinoma (18.6%). Therefore, NSBC’s drug treatment has received extensive attention. This article briefly introduces single